Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGL-193 in Advanced Parkinson's Disease
NCT06195124Phase 1Recruiting
- Sponsor
- The Second Affiliated Hospital of Soochow University
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label trial of RGL-193 in Parkinson's disease (PD) (2 arms), sponsored by The Second Affiliated Hospital of Soochow University. Primary endpoints: Number of patients with adverse events at 26 weeks, Number of patients with clinically significant change from baseline in vital signs value at 26 weeks and 4 more. Started Dec 2023; status: recruiting.
02
Drugs
RGL-193
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06195124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06195124.